ORIGINAL RESEARCH article
Front. Oncol.
Sec. Cancer Imaging and Image-directed Interventions
Clinical Efficacy of 99mTc-MIBI SPECT/CT Compared with CBCT in Lung Biopsies: A Retrospective Cohort Study
Provisionally accepted
- 1Inerventional radiology center, Suining Central Hospital, Sichuan, China
- 2Radiation Interventional Diagnosis and Treatment Center, Luzhou Longmatan Traditional Chinese Medicine Hospital, Sichuan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: This study aimed to evaluate the clinical value of 99mTc-MIBI SPECT/CT (Single-Photon Emission Computed Tomography/Computed Tomography) imaging-guided percutaneous lung aspiration biopsy by comparing its diagnostic accuracy and complication rates to those of CBCT-guided biopsy. METHODS: A total of 115 patients who underwent percutaneous lung aspiration biopsy at Suining Central Hospital from September 2019 to December 2020 were included. Patients were assigned to either the 99mTc-MIBI SPECT/CT-guided group (n = 34) or the CBCT-guided group (n = 81). Baseline characteristics, including age, sex, lesion location, type, and size, were statistically analyzed to ensure comparability. Bayesian multilevel logistic regression was utilized for subgroup analyses, and Clopper-Pearson exact intervals were calculated for accuracy metrics. Diagnostic accuracy and post-procedure complications were evaluated. In the SPECT/CT group, the target-to-background Ratio (TBR) uptake ratio was measured, and its predictive value for malignancy was assessed via ROC curve analysis. Interobserver reliability for TBR ratios was determined using the intraclass correlation coefficient (ICC). RESULTS: Baseline characteristics were comparable between groups (all p > 0.05). The SPECT/CT-guided group achieved 100% diagnostic accuracy, outperforming the CBCT-guided group (93.83%). Higher TBR ratios on SPECT/CT were strongly predictive of malignancy (AUC = 1.0, ICC = 0.938). For mass-type lesions 3–3.99 cm in diameter, SPECT/CT guidance yielded significantly higher accuracy than CBCT (p = 0.027, Posterior Probability of Superiority >96%). No significant accuracy differences were observed in other lesion locations, except for superior results in the left lower lobe with SPECT/CT. Complication rates were similar (23.53% vs. 16.05%, p > 0.05). CONCLUSION: 99mTc-MIBI SPECT/CT-guided biopsy serves as a promising exploratory tool for metabolic navigation in lung biopsies. It may offer incremental value in identifying viable tumor tissue within intermediate-sized masses without compromising safety. Given the pilot nature of this study, these findings are hypothesis-generating and necessitate confirmation through prospective, multicenter randomized trials.
Keywords: 99mTc-MIBI SPECT/CT imaging, complications, False-negative rate, Malignant lesions, percutaneous lung aspiration biopsy, Positive rate
Received: 02 Dec 2025; Accepted: 16 Feb 2026.
Copyright: © 2026 Yuan, Long, Yang, Wang, Yang, Jiang, Hu, Qin and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Wei Qin
Yakun Wu
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.